CHK2 Gene Polymorphism Analysis for Cancer Therapy Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer diagnosis and treatment methods are limited in predicting the course of cancer diseases, response to therapy, and occurrence of side effects due to individual variability in patients, particularly in relation to DNA repair mechanisms and genetic factors.
Innovation Solution
An in vitro method for predicting cancer disease risk and treatment response by analyzing specific gene modifications in the CHK2 gene, including polymorphisms −7161G>A, −7235C>G, −10532G>A, and −10649-(−10621)del29 in the promoter region of the CHK2 gene on chromosome 22q12.1, to modify protein expression or splicing variants and predict disease courses and therapy outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If classic staging and grading methods are used for cancer diagnosis, then the diagnosis process is simple and widely applicable, but the prediction accuracy for individual patient outcomes and therapy response is insufficient
Solution Approach 1:
The patent performs gene analysis of CHK2 polymorphisms before cancer treatment begins, allowing prediction of therapy response and side effects in advance. This preliminary genetic characterization enables clinicians to select appropriate therapies and adjust dosages before treatment starts, improving outcome prediction accuracy without adding complex diagnostic procedures during treatment.
Solution Approach 2:
The patent introduces genetic markers (CHK2 polymorphisms) as intermediary indicators that bridge the gap between simple staging/grading and complex individualized outcome prediction. These genetic markers serve as measurable intermediaries that correlate with therapy response and side effect susceptibility, providing enhanced prediction accuracy through a relatively simple genetic testing approach.
2Measurement precision
If gene analysis is performed to predict therapy effectiveness and side effects, then individualized treatment prediction is improved, but the complexity and cost of diagnosis increases
Solution Approach 1:
The patent extracts and analyzes only the specific CHK2 gene polymorphisms that are most relevant for predicting therapy response and side effects. By focusing on this particular genetic marker rather than performing comprehensive genomic analysis, the method achieves improved individualized treatment prediction while minimizing diagnostic complexity and cost through targeted genetic testing.
3Adaptability or versatility
If expensive biotechnological therapies are provided to all patients, then treatment accessibility is maximized, but resource efficiency and cost-effectiveness deteriorate
Solution Approach 1:
The patent applies different treatment strategies based on individual patient characteristics determined by CHK2 genotype analysis. Instead of providing expensive biotechnological therapies uniformly to all patients, the method identifies which patients are most likely to benefit from such treatments based on their genetic profile, thereby optimizing resource allocation and improving cost-effectiveness while maintaining accessibility for those who need it most.
Data Source
AI summary
The invention relates to the use of gene modifications in the human gene CHK2 (CHEK2), which encodes the checkpoint kinase 2, for predicting the risk and progression of cancer diseases, for predicting the response to pharmacological or non-pharmacological therapeutic measures for treating cancer diseases, and for predicting undesired effects of drugs. The invention further relates to the provision of individual gene variants with the help of which further gene modifications that can be used for the aforementioned purposes can be detected and validated. Such gene modifications can comprise a substitution of adenine for guanine in position −7161 in the promoter of CHK2, a substitution of guanine for cytosine in position −7235, a substitution of adenine for guanine in position −10532, or a deletion of 29 base pairs in positions −10621 to −10649.